Zaccheo T, Casazza A M, di Salle E, Pollini C, di Marco A
Eur J Cancer Clin Oncol. 1984 Sep;20(9):1193-7. doi: 10.1016/0277-5379(84)90129-9.
The effect of the new, prolactin-lowering ergoline derivative FCE21336 and medroxyprogesterone acetate (MPA) given alone and in combination was tested on DMBA-induced mammary tumors in rats. FCE 21336 (0.05 and 0.4 mg/kg p.o.) and MPA (25 and 50 mg/kg s.c.), administered 5 days/week for 4 weeks, inhibited the growth of established tumors and reduced serum prolactin levels. Combined treatment inhibited tumor growth more than single treatment. These results were confirmed in a second experiment: the antitumor effect of the combination of FCE 21336 (0.1 mg/kg p.o.) and MPA (50 mg/kg s.c.) was greater than that of the single treatment and was similar to the effect of ovariectomy. In this experiment rats with tumors that did not respond to 4 weeks' treatment with FCE 21336 (0.1 mg/kg p.o.) were treated during the next 4 weeks with MPA (50 mg/kg s.c.). MPA was effective on FCE 21336-unresponsive tumors. These data indicate that combined FCE 21336 and MPA treatment is more effective than single treatment and that MPA is effective on tumors not sensitive to the prolactin-lowering drug.
对新型降催乳素麦角林衍生物FCE21336和醋酸甲羟孕酮（MPA）单独及联合使用对二甲基苯并蒽（DMBA）诱导的大鼠乳腺肿瘤的作用进行了测试。FCE 21336（0.05和0.4毫克/千克，口服）和MPA（25和50毫克/千克，皮下注射），每周给药5天，持续4周，抑制了已形成肿瘤的生长并降低了血清催乳素水平。联合治疗比单一治疗更能抑制肿瘤生长。这些结果在第二个实验中得到证实：FCE 21336（0.1毫克/千克，口服）和MPA（50毫克/千克，皮下注射）联合使用的抗肿瘤作用大于单一治疗，且与卵巢切除术的效果相似。在该实验中，对用FCE 21336（0.1毫克/千克，口服）治疗4周无反应的肿瘤大鼠，在接下来的4周用MPA（50毫克/千克，皮下注射）进行治疗。MPA对FCE 21336无反应的肿瘤有效。这些数据表明，FCE 21336和MPA联合治疗比单一治疗更有效，且MPA对催乳素降低药物不敏感的肿瘤有效。
